Even with optimal glycemic control and statin therapy, many patients with type 2 diabetes remain at risk. Residual cardiovascular (CV) risk-often driven by atherogenic dyslipidemia and metabolic syndrome-continues to threaten long-term outcomes. Elevated triglycerides, low HDL-C, insulin resistance, and vascular complications remain common challenges.1 Fenofibrate (Lipway SR) offers targeted triglyceride-lowering therapy with proven metabolic and vascular benefits, complementing statins in patients with diabetic dyslipidemia.